Provided by Tiger Trade Technology Pte. Ltd.

ASCENTAGE-B

46.000
-0.600-1.29%
Volume:1.99M
Turnover:92.43M
Market Cap:17.16B
PE:-11.60
High:47.800
Open:46.700
Low:45.400
Close:46.600
52wk High:95.350
52wk Low:31.350
Shares:373.00M
HK Float Shares:373.00M
Volume Ratio:0.71
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-3.967
ROE:-154.56%
ROA:-23.02%
PB:11.40
PE(LYR):-11.60
PS:26.29

Loading ...

Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026

THOMSON REUTERS
·
Mar 11

ASCENTAGE-B (06855) Announces February 2026 Monthly Return

Bulletin Express
·
Mar 06

Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility

Simply Wall St.
·
Feb 28

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

Reuters
·
Feb 23

Is Ascentage Pharma Group International (SEHK:6855) Pricing Reflect A 23.3% One‑Year Gain?

Simply Wall St.
·
Feb 19

Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility

Simply Wall St.
·
Feb 14

Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Reuters
·
Feb 09

Ascentage Pharma Announces Ind Clearance by the China Cde for Btk Degrader Apg-3288

THOMSON REUTERS
·
Feb 06

China erteilt Ascentage Pharma IND-Genehmigung für BTK-Degrader APG-3288

Reuters
·
Feb 06

Ascentage Pharma (06855) Announces January 2026 Monthly Return

Bulletin Express
·
Feb 05

ASCENTAGE-B Stock Surges Over 3% in Intraday Trading as BTK Degrader Class 1 New Drug APG-3288 Tablets Gain Clinical Approval

Deep News
·
Feb 04

Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors

Reuters
·
Jan 15

A Look At Ascentage Pharma Group International's Valuation After FDA IND Clearance For APG-3288

Simply Wall St.
·
Jan 10

Hong Kong Stock Movement | ASCENTAGE-B (06855) Rises Nearly 4% as Novel BTK Degrader APG-3288's IND Application Receives US FDA Clearance

Stock News
·
Jan 07

FDA Clears IND for Ascentage Pharma’s BTK Degrader APG-3288

Reuters
·
Jan 07

Ascentage Pharma Announces Ind Clearance by the U.S. Food and Drug Administration for Btk Degrader Apg-3288

THOMSON REUTERS
·
Jan 07

ASCENTAGE PHARMA GROUP-B (06855): David Sidransky to be Appointed as Lead Independent Non-Executive Director

Stock News
·
Dec 30, 2025

Ascentage Pharma Group International Files Director List to HKEX

Reuters
·
Dec 30, 2025

Ascentage Pharma Appoints Dr. Debra Yu to Nomination Committee and Dr. David Sidransky as Lead Independent Director

Reuters
·
Dec 30, 2025

Assessing Ascentage Pharma (SEHK:6855) Valuation After New ASH 2025 Hematology Data on Olverembatinib and Lisaftoclax

Simply Wall St.
·
Dec 21, 2025